Mizuho Boosts DENTSPLY SIRONA Price Target

Wall Street firm sees potential 9% upside for the medical instruments supplier's stock.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Mizuho, a leading Wall Street research firm, has raised its price target for DENTSPLY SIRONA (NASDAQ:XRAY) stock from $14 to $16, representing a potential upside of nearly 9% from the stock's current trading price. The firm maintained its 'neutral' rating on the medical instruments supplier's shares.

Why it matters

DENTSPLY SIRONA is a major player in the dental products and technologies industry, so Mizuho's revised outlook could signal broader market sentiment and investor sentiment around the company's future performance and growth prospects.

The details

In its research note, Mizuho cited DENTSPLY SIRONA's recent financial results and market positioning as reasons for the price target increase, though the firm maintained its 'neutral' rating on the stock. The medical instruments supplier reported mixed Q4 2025 earnings in late February, with revenue beating expectations but earnings falling slightly short of analyst forecasts.

  • Mizuho issued its updated research note and price target on Monday, March 2, 2026.
  • DENTSPLY SIRONA reported its Q4 2025 financial results on Thursday, February 26, 2026.

The players

DENTSPLY SIRONA

A leading global manufacturer of professional dental products and technologies, headquartered in Charlotte, North Carolina.

Mizuho

A major Wall Street research firm that covers DENTSPLY SIRONA and other medical device companies.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

Mizuho's price target increase for DENTSPLY SIRONA suggests cautious optimism around the company's near-term outlook, though the firm's 'neutral' rating indicates there may still be some uncertainty around the dental products maker's long-term growth trajectory.